PRM 167

Drug Profile

PRM 167

Latest Information Update: 21 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Promedior
  • Class Anti-inflammatories; Antifibrotics; Glycoproteins; Recombinant proteins
  • Mechanism of Action Cell differentiation modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Retinal disorders

Most Recent Events

  • 21 Oct 2016 Preclinical development is ongoing for Age-related macular degeneration and Retinal disorders in USA (Promedior pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Intravitreous)
  • 31 Aug 2015 Promedior and Bristol Myers Squibb enter an agreement that grants Bristol Myers Squibb exclusive right to acquire Promedior
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top